Brazil's $280m Deal to Manufacture and Market Gaucher's Disease Drug
The Brazilian Government is to fund a new facility to produce the Protalix-Pfizer Gaucher's disease drug Uplyso as part of a supply and tech transfer deal worth $280m (€212m).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs